Try our beta test site
620 studies found for:    merkel cell carcinoma OR merkel cell cancer OR Neuroendocrine Carcinoma | merkel cell carcinoma OR merkel cell cancer OR Neuroendocrine Carcinoma
Show Display Options
Rank Status Study
21 Not yet recruiting Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
Condition: Neuroendocrine Carcinomas
Intervention: Drug: TLC 388
22 Not yet recruiting Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma
Condition: Pulmonary Large Cell Neuroendocrine Carcinoma
Interventions: Drug: etoposide plus carboplatin;   Drug: Paclitaxel plus carboplatin
23 Completed
Has Results
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Interventions: Drug: Avastin;   Drug: RAD001
24 Not yet recruiting Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
Condition: Neuroendocrine Carcinomas
Interventions: Drug: Folfiri-bevacizumab;   Drug: Folfiri
25 Completed Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Atiprimod
26 Completed Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Etoposide
27 Completed Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Atiprimod
28 Recruiting A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
Condition: Gastrointestinal Neuroendocrine Carcinomas
Interventions: Drug: NAB paclitaxel;   Drug: Carboplatin
29 Recruiting SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Conditions: Small Cell Lung Cancer;   Large Cell Neuroendocrine Carcinoma
Intervention: Drug: SC-002
30 Completed
Has Results
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Conditions: Neuroendocrine Carcinoma;   Islet Cell Carcinoma
Interventions: Drug: RAD001;   Drug: Octreotide Depot
31 Unknown  Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Condition: Well-differentiated Non-pancreatic Neuroendocrine Carcinoma
Interventions: Drug: Axitinib;   Drug: Sandostatin LAR;   Drug: Placebo
32 Active, not recruiting 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Condition: Neuroendocrine Carcinoma of the Lung and Thymus
Interventions: Drug: Pasireotide LAR;   Drug: Everolimus;   Drug: Pasireotide LAR + Everolimus
33 Completed Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Carcinoma of Unknown Primary;   Neuroendocrine Carcinoma;   Neuroendocrine Carcinoma of the Skin
Intervention: Drug: irinotecan hydrochloride
34 Completed BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions: Ovarian Cancer;   Merkel Cell Carcinoma;   SCLC
Intervention: Drug: BB-10901
35 Completed Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: Cixutumumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Octreotide Acetate;   Other: Pharmacological Study
36 Recruiting FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Conditions: Gastro-enteropancreatic Neuroendocrine Tumor;   Pancreatic Cancer;   Neuroendocrine Carcinomas of Pancreas;   Islet Cell Carcinoma
Interventions: Drug: FOLFIRINOX;   Drug: Granulocyte colony-stimulating factor (G-CSF)
37 Recruiting Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin
Condition: Neuroendocrine Carcinomas
Intervention: Drug: cisplatinum and everolimus
38 Recruiting Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Conditions: Poorly Differentiated Malignant Neuroendocrine Carcinoma;   Neuroendocrine Carcinoma, Grade 3;   Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3;   Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Intervention: Drug: Everolimus (Afinitor®)
39 Recruiting Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Everolimus
40 Not yet recruiting Octreotide LAR as Maintenance Treatment for Patients With NEC
Conditions: Gastro-entero-pancreatic Carcinoma;   Esophageal Neuroendocrine Carcinoma
Intervention: Drug: Octreotide lar

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.